Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 7/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 3/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27700750 | 0.94 | ASIC3 (0.58) | ASIC3DRD2DRD3CD274DDB1 | |
| Hydrochloric Acid SCHEMBL587643 | 0.93 | ASIC3 (0.56) | ASIC3DRD2DRD3CD274DDB1 | |
| Hydrochloric Acid SCHEMBL587096 | 0.79 | ASIC3 (0.40) | ASIC3DRD2DRD3CD274DDB1 | |
| SCHEMBL3337600 | 0.77 | ASIC3 (0.60) | ASIC3DRD2DRD3CD274PNMT | |
| SCHEMBL27721456 | 0.76 | ASIC3 (0.59) | ASIC3DRD2DRD3CD274PNMT | |
| Hydrochloric Acid SCHEMBL588201 | 0.75 | ASIC3 (0.58) | ASIC3DRD2DRD3CD274PNMT | |
| SCHEMBL1010614 | 0.72 | ASIC3 (0.61) | ASIC3DRD2DRD3CD274PNMT | |
| SCHEMBL3126396 | 0.72 | ASIC3 (0.55) | ASIC3DRD2DRD3DDB1CRBN | |
| SCHEMBL6347388 | 0.72 | ASIC3 (0.65) | ASIC3DRD2DRD3CD274PNMT | |
| Hydrochloric Acid SCHEMBL587196 | 0.71 | ASIC3 (0.44) | ASIC3DRD2DRD3CD274DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831199-B1 | MMP inhibitors | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| US-7655664-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1831199-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | ASIC3 3925/4885DRD2 2638/4885DRD3 2849/4885 |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | ASIC3 3925/4885DRD2 2638/4885DRD3 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.